Cue Biopharma, Inc. 8-K

What Happened
Cue Biopharma announced on an 8‑K that four directors — Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen — resigned effective May 29, 2026. The Board approved a reduction in size from seven directors to five effective June 1, 2026, and on May 30–June 1, 2026 appointed two new directors and two senior officers. Sumita Ray, JD, was appointed Chief Legal & Compliance Officer and Corporate Secretary effective June 1, 2026 (succeeding Colin Sandercock, who will remain Senior VP, Intellectual Property). Michael Meluzio was named Vice President, Principal Accounting Officer effective June 1, 2026. Daniel Camardo and Viola Meehan were appointed to the Board on May 30, 2026 for one‑year terms.

Key Details

• Four directors (Broadfoot, Kiener, Morich, Verheyen) resigned effective May 29, 2026; resignations were not due to any disagreement with the Company.
• Board size reduced from seven to five directors, effective June 1, 2026.
• Sumita Ray appointed Chief Legal & Compliance Officer & Corporate Secretary (effective June 1, 2026); prior roles include Chief Legal & Compliance positions at Vaxxinity, Instil Bio, and Calithera.
• Michael Meluzio (age 42), a NY CPA, promoted to VP, Principal Accounting Officer (effective June 1, 2026); previously VP of Finance and Corporate Controller at Cue.
• Daniel Camardo appointed chair of the Nominating & Corporate Governance Committee and member of Audit and Compensation Committees; Viola Meehan appointed chair of the Audit Committee and member of the Compensation Committee. New committee chairs: Meehan (Audit), Pamela Garzone (Compensation), Camardo (Nominating).
• New directors will receive standard director cash and equity compensation per the company’s director policy and will enter Cue’s standard indemnification agreement.

Why It Matters
These governance and senior‑officer changes affect who oversees compliance, legal matters and financial reporting at Cue. Appointing a new Chief Legal & Compliance Officer and formalizing a principal accounting officer clarifies responsibility for legal/regulatory and accounting oversight—important for investor confidence and SEC reporting. The board reduction and new directors change the composition and committee leadership (notably Audit and Nominating), which can influence governance, oversight of strategy, and review of company financials and risk. All changes reported are factual and procedural; the filing states resignations were not due to disagreements with the company.